Gene therapy for prostate cancer

Yehoshua Gdor, Terry L. Timme, Brian J. Miles, Dov Kadmon, Timothy C. Thompson

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


Prostate cancer is the most common noncutaneous cancer in man. When confined to the prostate it can be cured by radical prostatectomy or irradiation therapy. However, there are no curative therapies for locally advanced, recurrent or metastatic disease. Prostate cancer gene therapy has recently transitioned from preclinical studies to clinical trials with the goal of developing novel treatments for prostate cancer. The greatest challenge in treating advanced prostate cancer is therapeutic access to and the elimination of metastases. This review details two aspects of prostate cancer gene therapy, the types of delivery systems under development and specific categories of therapeutic genes available with an emphasis on the mechanism of action of specific gene therapy strategies.

Original languageEnglish (US)
Pages (from-to)309-321
Number of pages13
JournalExpert Review of Anticancer Therapy
Issue number3
StatePublished - Jan 1 2002


  • Adenovirus
  • Gene therapy
  • HSV-tk
  • IL-12
  • Immunotherapy
  • Metastasis
  • Prostate cancer

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research


Dive into the research topics of 'Gene therapy for prostate cancer'. Together they form a unique fingerprint.

Cite this